EB 201 - Estrella Immunopharma
Alternative Names: EB-201 - Estrella ImmunopharmaLatest Information Update: 22 Jan 2025
Price :
$50 *
At a glance
- Originator Estrella Immunopharma
- Class Gene therapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Systemic lupus erythematosus
Most Recent Events
- 05 Sep 2024 Preclinical trials in Systemic lupus erythematosus in USA (Parenteral), prior to September 2024 (Estrella Immunopharma pipeline, September 2024)